# Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)

> **NCT00446134** · PHASE2 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 278 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Taribavirin
- **DRUG:** Taribavirin
- **DRUG:** Taribavirin
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00446134
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-04
- **Final completion:** 2009-04
- **Target enrollment:** 278 (ACTUAL)
- **Last updated:** 2012-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00446134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00446134, "Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00446134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*